Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 9, 2008, Pages 1384-1389

  Huang, Yu Chuen ^a,b   Chen, Marcelo ^a,b,c   Shyr, Yi Ming ^d   Su, Cheng Hsi ^d   Chen, Chi Kuan ^b   Li, Anna Fen Yau ^d   Ho, Donald Ming Tak ^d   Chen, Yi Ming Arthur ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cholangiocarcinoma; Glycine N methyltransferase; Hepatocellular carcinoma; Immunohistochemistry

Indexed keywords

GLYCINE METHYLTRANSFERASE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 49849084374     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05488.x     Document Type: Article

References (26)

1. Parkin DM, Ohshima H, Srivatanakul P, Vatanasapt V. Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol. Biomarkers Prev. 1993 2 : 537 44.
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001 33 : 1353 7.
3. Chamberlain RS, Blumgart LH. Hilar cholangiocarcinoma: a review and commentary. Ann. Surg. Oncol. 2000 7 : 55 66.
4. Chen YM, Shiu JY, Tzeng SJ et al. Characterization of glycine-N-methyltransferase-gene expression in human hepatocellular carcinoma. Int. J. Cancer 1998 75 : 787 93.
5. Chen YM, Chen LY, Wong FH, Lee CM, Chang TJ, Yang-Feng TL. Genomic structure, expression, and chromosomal localization of the human glycine N-methyltransferase gene. Genomics 2000 66 : 43 7.
6. Tseng TL, Shih YP, Huang YC et al. Genotypic and phenotypic characterization of a putative tumor susceptibility gene, GNMT, in liver cancer. Cancer Res. 2003 63 : 647 54.
7. Yeo EJ, Wagner C. Tissue distribution of glycine N-methyltransferase, a major folate-binding protein of liver. Proc. Natl Acad. Sci. USA 1994 91 : 210 4.
8. Kerr SJ. Competing methyltransferase systems. J. Biol. Chem. 1972 247 : 4248 52.
9. Chen SY, Lin JR, Darbha R, Lin P, Liu TY, Chen YM. Glycine N-methyltransferase tumor susceptibility gene in the benzo(a)pyrene- detoxification pathway. Cancer Res. 2004 64 : 3617 23.
10. Augoustides-Savvopoulou P, Luka Z, Karyda S et al. Glycine N-methyltransferase deficiency: a new patient with a novel mutation. J. Inherit. Metab. Dis. 2003 26 : 745 59.
11. Mudd SH, Cerone R, Schiaffino MC et al. Glycine N-methyltransferase deficiency: a novel inborn error causing persistent isolated hypermethioninaemia. J. Inherit. Metab. Dis. 2001 24 : 448 64.
12. Greene FL, Page DL, Fleming ID et al., eds. AJCC Cancer Staging Manual, 6th edn. New York : Springer, 2002.
13. Liu HH, Chen KH, Shih YP, Lui WY, Wong FH, Chen YM. Characterization of reduced expression of glycine N-methyltransferase in cancerous hepatic tissues using two newly developed monoclonal antibodies. J. Biomed. Sci. 2003 10 : 87 97.
14. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999 17 : 1474 81.
15. Lai MC, Yang DR, Chuang MJ. Regulatory factors associated with synthesis of the osmolyte glycine betaine in the halophilic methanoarchaeon Methanohalophilus portucalensis. Appl. Environ. Microbiol. 1999 65 : 828 33.
16. Aida K, Tawata M, Negishi M, Onaya T. Mouse glycine N-methyltransferase is sexually dimorphic and regulated by growth hormone. Horm. Metab. Res. 1997 29 : 646 9.
17. Liu SP, Li YS, Chen YJ et al. Glycine N-methyltransferase-/- mice develop chronic hepatitis and glycogen storage disease in the liver. Hepatology 2007 46 : 1413 25.
18. Borscheri N, Roessner A, Rocken C. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am. J. Surg. Pathol. 2001 25 : 1297 303.
19. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum. Pathol. 2002 33 : 1175 81.
20. Xiao SY, Wang HL, Hart J, Fleming D, Beard MR. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma. Am. J. Pathol. 2001 159 : 1415 21.
21. Wang L, Vuolo M, Suhrland MJ, Schlesinger K. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol. 2006 50 : 257 62.
22. Mazal PR, Susani M, Wrba F, Haitel A. Diagnostic significance of aquaporin-1 in liver tumors. Hum. Pathol. 2005 36 : 1226 31.
23. Christensen WN, Boitnott JK, Kuhajda FP. Immunoperoxidase staining as a diagnostic aid for hepatocellular carcinoma. Mod. Pathol. 1989 2 : 8 12.
24. Leong AS, Sormunen RT, Tsui WM, Liew CT. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology 1998 33 : 318 24.
25. Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am. J. Surg. Pathol. 2002 26 : 978 88.
26. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am. J. Pathol. 1993 143 : 1050 4.